NEUMÜNSTER, Germany, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), proudly announces that its German subsidiary, Tilray Deutschland GmbH, has secured a tender to supply Luxembourg with its high-quality cannabis flower. The granting of this tender by the Ministry of Health and Social Security for the Grand Duchy of Luxembourg highlights the trust placed in Tilray Medical to deliver high-quality medical cannabis on a consistent basis across the global medical cannabis industry. Additionally, it reinforces Tilray’s commitment to deliver on Europe’s growing demand for premium medical cannabis products.

Denise Faltischek, Chief Strategy Officer and Head of International, said, "We are honored to have been selected again to supply medical cannabis to Luxembourg. This is a testament to the unwavering dedication of our team in providing patients around the world with high-quality medical cannabis products."

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Broken Coast, Redecan, Good Supply and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Portugal and Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments in over 20 countries and across five continents.

Further information can also be found here: Pioneering the Future of Medical Cannabis - Tilray EU

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information:
Media: news@tilray.com
Investor Relations: investors@tilray.com

This item of content is a press release from a third party provider who make no warranties or representations in connection with this content and therefore PA can make no warranties in respect of its use.

Tags

More Like This

Tilray Expands Medical Cannabis Portfolio in Germany

Tilray Medical Brings Canada’s Iconic Cannabis Brand Good Supply to Germany

Tilray Medical Launches its First Commercial “Grown in Germany” Medical Cannabis Products Under its Newly Expanded Cultivation License

Tilray Provides International Cannabis Update on Milestone German Cannabis Legalization

Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany

Tilray Medical Launches Tilray Craft: Introducing High THC, High Terpene Genetics to the German Medical Cannabis Market

Tilray Medical Receives Approval for First Medical Cannabis Extract in Portugal

Tilray’s Aphria RX Receives Cannabis Trading License in Germany, Significantly Expanding Commercial Growth Opportunities